Stocks & Investing
Tue, September 17, 2024
[ Tue, Sep 17th 2024
] - WOPRAI
Wed, August 21, 2024
[ Wed, Aug 21st 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
Thu, June 27, 2024
[ Thu, Jun 27th 2024
] - WOPRAI
Thu, May 9, 2024
[ Thu, May 09th 2024
] - WOPRAI
Mon, March 25, 2024
[ Mon, Mar 25th 2024
] - WOPRAI
Tue, February 27, 2024
[ Tue, Feb 27th 2024
] - WOPRAI
Thu, December 21, 2023
[ Thu, Dec 21st 2023
] - WOPRAI
Mon, December 18, 2023
[ Mon, Dec 18th 2023
] - WOPRAI
Thu, December 14, 2023
[ Thu, Dec 14th 2023
] - WOPRAI
[ Thu, Dec 14th 2023
] - WOPRAI
Wed, November 22, 2023
[ Wed, Nov 22nd 2023
] - WOPRAI
Tue, November 14, 2023
[ Tue, Nov 14th 2023
] - WOPRAI
Tue, November 7, 2023
[ Tue, Nov 07th 2023
] - WOPRAI
Thu, September 14, 2023
[ Thu, Sep 14th 2023
] - WOPRAI
Tue, August 8, 2023
[ Tue, Aug 08th 2023
] - WOPRAI
Tue, August 1, 2023
[ Tue, Aug 01st 2023
] - WOPRAI
Tue, July 25, 2023
[ Tue, Jul 25th 2023
] - WOPRAI
Tue, June 6, 2023
[ Tue, Jun 06th 2023
] - WOPRAI
Tue, May 2, 2023
[ Tue, May 02nd 2023
] - WOPRAI
Tue, February 28, 2023
[ Tue, Feb 28th 2023
] - WOPRAI
Thu, February 9, 2023
[ Thu, Feb 09th 2023
] - WOPRAI
Sun, October 30, 2022
[ Sun, Oct 30th 2022
] - WOPRAI
Thu, October 13, 2022
[ Thu, Oct 13th 2022
] - WOPRAI
Mon, September 12, 2022
[ Mon, Sep 12th 2022
] - WOPRAI
Wed, August 10, 2022
[ Wed, Aug 10th 2022
] - WOPRAI
Thu, June 23, 2022
[ Thu, Jun 23rd 2022
] - WOPRAI
Thu, May 5, 2022
[ Thu, May 05th 2022
] - WOPRAI
Tue, March 8, 2022
[ Tue, Mar 08th 2022
] - WOPRAI
[ Tue, Mar 08th 2022
] - WOPRAI
Paul Matteis Maintained (BMRN) at Strong Buy with Decreased Target to $87 on, Sep 17th, 2024
Paul Matteis of Stifel, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $115 to $87 on, Sep 17th, 2024.
Paul has made no other calls on BMRN in the last 4 months.
There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 2 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $93 on, Friday, September 13th, 2024
- Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
These are the ratings of the 6 analyists that currently disagree with Paul
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, September 9th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $122 on, Thursday, September 5th, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $120 on, Thursday, September 5th, 2024
- Cory Kasimov of "Evercore ISI Group" Maintained at Buy with Increased Target to $115 on, Tuesday, August 6th, 2024
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $110 on, Tuesday, August 6th, 2024
- Phil Nadeau of "TD Cowen" Maintained at Strong Buy with Decreased Target to $120 on, Tuesday, August 6th, 2024
